Overview: Hepatitis B Surface Antigen Confirmatory TestIntroduction: The Hepatitis B Surface Antigen Confirmatory Test confirms hepatitis B surface antigen to diagnose active infection, causing jaundice or fatigue. Following 2023 AASLD guidelines, it uses an immunoassay for high specificity, aiding in infectious disease screening. This test is critical for guiding diagnosis, antiviral therapy, and improving outcomes in serology for patients with suspected hepatitis B infection.
Other Names: HBsAg Confirm Assay, Hepatitis B Confirmatory Test.
FDA Status: FDA-cleared diagnostic test, meeting serology standards for diagnostic accuracy.
Historical Milestone: HBsAg testing began in the 1970s with HBV discovery. Confirmatory immunoassays improved in the 1980s, enhancing diagnostic specificity.
Purpose: Confirms active hepatitis B infection, guides antiviral therapy, and monitors HBsAg in patients with jaundice or fatigue.
Test Parameters: 1. Hepatitis B Surface Antigen
Pretest Condition: No fasting required. Collect serum at any time. Report symptoms like jaundice, fatigue, or liver pain, and list medications or vaccination history.
Specimen: 2-5 mL serum (SST). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document jaundice, fatigue, liver pain, or history of hepatitis B. Include current medications, vaccination status, or risk factors (e.g., IV drug use).
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for antiviral therapy.
Procedural Considerations: Uses an immunoassay to confirm HBsAg presence. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Recent vaccination, hemolysis, or improper storage can affect results. Early infection may yield false negatives.
Clinical Significance: Positive HBsAg confirms active hepatitis B, prompting antiviral therapy. Negative results may require further testing to rule out early infection.
Specialist Consultation: Consult a hepatologist or infectious disease specialist for result interpretation and treatment planning.
Additional Supporting Tests: HBV DNA, anti-HBc, or liver function tests to confirm hepatitis B and assess liver damage.
Test Limitations: False negatives may occur in early infection or low viral load. Clinical correlation is needed.
References: AASLD Hepatitis B Guidelines, 2023; Hepatology, Lok AS, 2022.
